Evidence map›Paper›PMID 42653011›Full record

ArticleLife (Basel, Switzerland)2026

Longitudinal Outcomes and Ribavirin Use in Lung Transplant Recipients with Respiratory Syncytial Virus or Human Metapneumovirus Infection: A Real-World Multicenter Cohort Study.

Miguel Jiménez-Gómez, Beatriz Montull-Veiga, Víctor Manuel Mora-Cuesta, Eva Revilla-López, Myriam Aguilar-Pérez, Alicia de-Pablo-Gafas, Juan Margallo-Iribarnegaray, Carlos Andrés Quezada-Loaiza, Ana Hernández-Voth, Francisco López-Medrano and 2 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Miguel Jiménez-GómezLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.ORCID 0000-0002-3525-564X
Beatriz Montull-VeigaLung Transplant Unit, Pulmonology Department, La Fe de Valencia University Hospital, 46026 Valencia, Spain.
Víctor Manuel Mora-CuestaLung Transplant Unit, Pulmonology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.ORCID 0000-0002-8161-0462
Eva Revilla-LópezLung Transplant Unit, Pulmonology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Myriam Aguilar-PérezLung Transplant Unit, Pulmonology Department, Puerta de Hierro University Hospital, 28222 Madrid, Spain.
Alicia de-Pablo-GafasLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Juan Margallo-IribarnegarayLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Carlos Andrés Quezada-LoaizaLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Ana Hernández-VothInstituto de Investigación Hospital "12 de Octubre" (i+12), 12 de Octubre University Hospital, 28041 Madrid, Spain.ORCID 0000-0003-0601-6954
Francisco López-MedranoInstituto de Investigación Hospital "12 de Octubre" (i+12), 12 de Octubre University Hospital, 28041 Madrid, Spain.ORCID 0000-0001-5333-7529
María Ruiz-RodríguezLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Rodrigo Alonso-MoralejoLung Transplant Unit, Pulmonology Department, 12 de Octubre University Hospital, 28041 Madrid, Spain.ORCID 0000-0002-7833-5084

Funding

Neumomadrid Premio investigación
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are clinically relevant pathogens in lung transplant (LT) recipients, but their impact on lung function and the benefit of ribavirin remains uncertain. We conducted a prospective multicenter observational cohort study of adult LT recipients with RSV or hMPV infection diagnosed between 2021 and 2024 at five centers, with follow-up for up to 12 months. Ribavirin was prescribed at the treating physician's discretion. Multivariable analysis assessed the association between ribavirin and percentage change in forced expiratory volume in the first second (FEV

Indexed as

human metapneumoviruslung allograft dysfunctionrespiratory syncytial virusrespiratory viral infectionribavirin

Identifiers

PMID42653011
PMCPMC13514294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.